Optimizing the Use of Ipilimumab/Nivolumab in mRCC

preview_player
Показать описание
Regarding the management of adverse events and appropriate patient selection, panelists provide insight on the optimal delivery of ipilimumab + nivolumab for metastatic renal cell carcinoma (mRCC).
  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Optimizing the Use 0:03:16

Optimizing the Use of Ipilimumab/Nivolumab in mRCC

Treatment-free survival results 0:06:16

Treatment-free survival results of nivolumab and salvage nivolumab + ipilimumab for accRCC

Combination Nivolumab and 0:00:58

Combination Nivolumab and Ipilimumab Shows Efficacy in Advanced Melanoma

Metastatic RCC: Using 0:06:01

Metastatic RCC: Using Frontline Ipilimumab/Nivolumab

Nivolumab and Ipilimumab 0:01:05

Nivolumab and Ipilimumab Combination in Frontline mCRC

FDA Approval of 0:01:34

FDA Approval of Frontline Nivolumab/Ipilimumab Combo in RCC

Dr. Patel on 0:01:09

Dr. Patel on Benefit of Ipilimumab/Nivolumab Combo in High-Grade Neuroendocrine Carcinoma

Comment: Nivolumab plus 0:03:14

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

mRCC Patient Selection 0:07:36

mRCC Patient Selection for Ipilimumab/Nivolumab

Nivolumab with alternatively 0:09:09

Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC

I-O Therapy in 0:05:19

I-O Therapy in mCRC: Ipilimumab + Nivolumab

Dr. Kluger on 0:01:30

Dr. Kluger on Toxicity of Nivolumab/ Ipilimumab for Advanced Melanoma

Front-line therapy with 0:08:26

Front-line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced RCC

Dr. Chiang Discusses 0:01:27

Dr. Chiang Discusses Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

Longterm Benefits from 0:02:00

Longterm Benefits from Nivolumab and Ipilimumab Combination Therapy

Nivolumab plus ipilimumab 0:03:46

Nivolumab plus ipilimumab continues to improve OS, PFS at 2 years in patients with advanced melanoma

Dr. Motzer on 0:01:08

Dr. Motzer on Nivolumab/Ipilimumab Activity in RCC

CheckMate-227: Nivolumab + 0:05:31

CheckMate-227: Nivolumab + Ipilimumab in mNSCLC

Dr. Pal on 0:00:51

Dr. Pal on the Frontline Approval of Nivolumab and Ipilimumab in mRCC

CheckMate 067: Nivolumab 0:01:13

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma

Checkmate 067 - 0:03:59

Checkmate 067 - combined nivolumab and ipilimumab

Dr. Long on 0:02:11

Dr. Long on Rationale for Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain Mets

Investigating Responses to 0:01:55

Investigating Responses to Nivolumab and Ipilimumab in Advanced RCC

Dr. McDermott on 0:01:24

Dr. McDermott on Nivolumab Plus Ipilimumab in RCC

welcome to shbcf.ru